20240309_am24_abstract_topic_model
This is a BERTopic model. BERTopic is a flexible and modular topic modeling framework that allows for the generation of easily interpretable topics from large datasets.
Usage
To use this model, please install BERTopic:
pip install -U bertopic
You can use the model as follows:
from bertopic import BERTopic
topic_model = BERTopic.load("djordan/20240309_am24_abstract_topic_model")
topic_model.get_topic_info()
Topic overview
- Number of topics: 175
- Number of training documents: 8265
Click here for an overview of all topics.
Topic ID | Topic Keywords | Topic Frequency | Label |
---|---|---|---|
-1 | Immunotherapy and Tumor Microenvironment - - - - | 5 | Immunotherapy and Tumor Microenvironment |
0 | Cancer Survival and Healthcare Access - - - - | 3778 | Cancer Survival and Healthcare Access |
1 | |||
Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies - - - - | 429 | Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies | |
2 | Glioblastoma research and treatment - - - - | 186 | Glioblastoma research and treatment |
3 | "3D Organoid Culture in Cancer Research" - - - - | 168 | 3D Organoid Culture in Cancer Research |
4 | Kras G12C Inhibitors and Resistance - - - - | 160 | Kras G12C Inhibitors and Resistance |
5 | |||
Acute Myeloid Leukemia Treatment and Drug Screening - - - - | 154 | Acute Myeloid Leukemia Treatment and Drug Screening | |
6 | Spatial imaging of tissue microenvironments - - - - | 120 | Spatial imaging of tissue microenvironments |
7 | Prostate cancer and AR degradation - - - - | 112 | Prostate cancer and AR degradation |
8 | Parp Inhibition and DNA Damage Repair - - - - | 110 | Parp Inhibition and DNA Damage Repair |
9 | Pancreatic Ductal Adenocarcinoma (PDAC) Microenvironment - - - - | 99 | Pancreatic Ductal Adenocarcinoma Microenvironment |
10 | Topoisomerase 1 Inhibitors Adc Development - - - - | 92 | Topoisomerase 1 Inhibitors Adc Development |
11 | Hepatocellular Carcinoma Treatment Research - - - - | 85 | Hepatocellular Carcinoma Treatment Research |
12 | EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer - - - - | 78 | EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer |
13 | Glutamine Metabolism in Cervical Cancer - - - - | 76 | Glutamine Metabolism in Cervical Cancer |
14 | |||
"Nanoparticle-based cancer treatment" - - - - | 67 | Nanoparticle-based cancer treatment | |
15 | Bone metastasis in breast cancer - - - - | 56 | Bone metastasis in breast cancer |
16 | Microbiome and Immunotherapy in Cancer - - - - | 54 | Microbiome and Immunotherapy in Cancer |
17 | Triple Negative Breast Cancer (TNBC) - - - - | 51 | Triple Negative Breast Cancer |
18 | |||
Oral Squamous Cell Carcinoma (OSCC) Research - - - - | 48 | Oral Squamous Cell Carcinoma Research | |
19 | Melanoma therapy and Braf inhibitors - - - - | 46 | Melanoma therapy and Braf inhibitors |
20 | Immunomodulation of Glioblastoma with Sting Agonism - - - - | 45 | Immunomodulation of Glioblastoma with Sting Agonism |
21 | |||
"Anticancer mechanisms of natural compounds" - - - - | 41 | Anticancer mechanisms of natural compounds | |
22 | Renal Cell Carcinoma Subtypes - - - - | 41 | Renal Cell Carcinoma Subtypes |
23 | |||
"Liquid Biopsy Using Urine and Plasma Samples" - - - - | 40 | Liquid Biopsy Using Urine and Plasma Samples | |
24 | Award ceremony speech draft - - - - | 39 | Award ceremony speech draft |
25 | |||
TCR-engineered therapy for cancer treatment - - - - | 38 | TCR-engineered therapy for cancer treatment | |
26 | T-cell engagers for cancer treatment - - - - | 38 | T-cell engagers for cancer treatment |
27 | Colorectal cancer research - - - - | 37 | Colorectal cancer research |
28 | Obesity and breast cancer - - - - | 36 | Obesity and breast cancer |
29 | Ferroptosis in cancer treatment - - - - | 36 | Ferroptosis in cancer treatment |
30 | Trop2-targeted ADCs for cancer treatment - - - - | 34 | Trop2-targeted ADCs for cancer treatment |
31 | Hippo pathway inhibitors - - - - | 34 | Hippo pathway inhibitors |
32 | Immunotherapy in mice - - - - | 33 | Immunotherapy in mice |
33 | |||
Clinical trials of immunotherapies - - - - | 32 | Clinical trials of immunotherapies | |
34 | Immunity checkpoint inhibitors and resistance - - - - | 29 | Immunity checkpoint inhibitors and resistance |
35 | Pancreatic cancer research - - - - | 29 | Pancreatic cancer research |
36 | Drug combination screening - - - - | 28 | Drug combination screening |
37 | |||
Pancreatic Cancer Research - - - - | 27 | Pancreatic Cancer Research | |
38 | Her2 expression in solid tumors - - - - | 26 | Her2 expression in solid tumors |
39 | Smoking-induced lung cancer research - - - - | 26 | Smoking-induced lung cancer research |
40 | |||
"Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer" - - - - | 26 | Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer | |
41 | Prostate cancer research and treatment - - - - | 25 | Prostate cancer research and treatment |
42 | Cyclin-dependent kinase 2 inhibition in cancer therapy - - - - | 25 | Cyclin-dependent kinase 2 inhibition in cancer therapy |
43 | |||
"Methylation Detection from Cell-Free DNA" - - - - | 25 | Methylation Detection from Cell-Free DNA | |
44 | Medulloblastoma research and treatment - - - - | 25 | Medulloblastoma research and treatment |
45 | Single-cell RNA sequencing and chromatin accessibility analysis - - - - | 24 | Single-cell RNA sequencing and chromatin accessibility analysis |
46 | |||
"MTA-PRMT5 Inhibitors for Cancer Treatment" - - - - | 24 | MTA-PRMT5 Inhibitors for Cancer Treatment | |
47 | Anti-PD-1 therapy in NSCLC - - - - | 24 | Anti-PD-1 therapy in NSCLC |
48 | Immunomodulation with IL-18 and PD-1 antagonists - - - - | 24 | Immunomodulation with IL-18 and PD-1 antagonists |
49 | RMS and Pax3-Foxo1 Fusion Protein Research - - - - | 24 | RMS and Pax3-Foxo1 Fusion Protein Research |
50 | |||
"Chromatin organization and gene regulation in breast cancer" - - - - | 24 | Chromatin organization and gene regulation in breast cancer | |
51 | Multi-Cancer Early Detection Tests - - - - | 23 | Multi-Cancer Early Detection Tests |
52 | |||
Mitochondrial dysfunction in cancer - - - - | 23 | Mitochondrial dysfunction in cancer | |
53 | Cholangiocarcinoma research and treatments - - - - | 23 | Cholangiocarcinoma research and treatments |
54 | Immune cell analysis with cytof - - - - | 23 | Immune cell analysis with cytof |
55 | |||
"Circulating Tumor DNA Monitoring in Cancer Treatment" - - - - | 23 | Circulating Tumor DNA Monitoring in Cancer Treatment | |
56 | Cellular thermal shift assay (CTSA) for target engagement - - - - | 22 | Cellular thermal shift assay for target engagement |
57 | "FFPE Library Prep Methods" - - - - | 21 | FFPE Library Prep Methods |
58 | |||
"Lung Cancer Classification and Targeting" - - - - | 21 | Lung Cancer Classification and Targeting | |
59 | Immunotherapy biomarkers in cancer patients - - - - | 20 | Immunotherapy biomarkers in cancer patients |
60 | Colorectal cancer genomics and mutations - - - - | 20 | Colorectal cancer genomics and mutations |
61 | Epithelial-mesenchymal transition and plasticity in cancer - - - - | 20 | Epithelial-mesenchymal transition and plasticity in cancer |
62 | Electric fields for cancer treatment - - - - | 19 | Electric fields for cancer treatment |
63 | Cancer-associated fibroblasts in tumor microenvironment - - - - | 19 | Cancer-associated fibroblasts in tumor microenvironment |
64 | |||
Prostate cancer research and diagnosis - - - - | 19 | Prostate cancer research and diagnosis | |
65 | |||
Acquired drug resistance and persister cells - - - - | 19 | Acquired drug resistance and persister cells | |
66 | |||
"EAC and Barrett's Esophagus Research" - - - - | 19 | EAC and Barrett's Esophagus Research | |
67 | |||
"Lung Cancer Research" - - - - | 18 | Lung Cancer Research | |
68 | |||
"Cachexia and Muscle Wasting in Cancer Patients" - - - - | 18 | Cachexia and Muscle Wasting in Cancer Patients | |
69 | Cloud-based data governance for cancer research - - - - | 17 | Cloud-based data governance for cancer research |
70 | Ewing Sarcoma Research - - - - | 17 | Ewing Sarcoma Research |
71 | |||
"Immunotherapy targeting Tregs" - - - - | 16 | Immunotherapy targeting Tregs | |
72 | |||
Nano-immunotherapy for cancer treatment - - - - | 16 | Nano-immunotherapy for cancer treatment | |
73 | |||
"Trial of T-1101 and T-1201 in Cancer Treatment" - - - - | 16 | Trial of T-1101 and T-1201 in Cancer Treatment | |
74 | Radiation and Immunity in Cancer Treatment - - - - | 16 | Radiation and Immunity in Cancer Treatment |
75 | Immunotherapy and Neoantigens - - - - | 15 | Immunotherapy and Neoantigens |
76 | Aging and immune system in cancer - - - - | 15 | Aging and immune system in cancer |
77 | |||
Progesterone and breast cancer - - - - | 14 | Progesterone and breast cancer | |
78 | |||
"Gut Microbiome in CRC Patients" - - - - | 14 | Gut Microbiome in CRC Patients | |
79 | Hematopoiesis and Clonal Variants - - - - | 14 | Hematopoiesis and Clonal Variants |
80 | |||
"Kinase Inhibition and Targeting" - - - - | 14 | Kinase Inhibition and Targeting | |
81 | Paralog selective degraders for cancer therapy - - - - | 13 | Paralog selective degraders for cancer therapy |
82 | |||
"Immunotherapy for Melanoma" - - - - | 13 | Immunotherapy for Melanoma | |
83 | Genome-scale measurements for tumor normal benchmark - - - - | 13 | Genome-scale measurements for tumor normal benchmark |
84 | Immunotherapy for bladder cancer - - - - | 13 | Immunotherapy for bladder cancer |
85 | Hematopoietic Progenitor Kinase 1 Inhibition - - - - | 13 | Hematopoietic Progenitor Kinase 1 Inhibition |
86 | |||
Variants of Uncertain Significance (VUS) - - - - | 13 | Variants of Uncertain Significance | |
87 | |||
"Colorectal cancer detection" - - - - | 13 | Colorectal cancer detection | |
88 | Claudin18 Targeted Therapy - - - - | 13 | Claudin18 Targeted Therapy |
89 | |||
"AI-based tumor purity analysis" - - - - | 13 | AI-based tumor purity analysis | |
90 | Bispecific antibody development for cancer treatment - - - - | 13 | Bispecific antibody development for cancer treatment |
91 | |||
"Genomic Variant Detection" - - - - | 12 | Genomic Variant Detection | |
92 | Prostate cancer in African men - - - - | 12 | Prostate cancer in African men |
93 | |||
"Microsatellite Instability and WRN Helicase Inhibition" - - - - | 12 | Microsatellite Instability and WRN Helicase Inhibition | |
94 | Immunosuppression and antibody-enhancing drugs - - - - | 12 | Immunosuppression and antibody-enhancing drugs |
95 | |||
"Immune Checkpoint Inhibitor Adverse Events" - - - - | 12 | Immune Checkpoint Inhibitor Adverse Events | |
96 | Neuronal influence on cancer growth - - - - | 12 | Neuronal influence on cancer growth |
97 | "Uveal Melanoma and Selenoproteome Expression" - - - - | 11 | Uveal Melanoma and Selenoproteome Expression |
98 | HBV and HCC Treatment Studies - - - - | 11 | HBV and HCC Treatment Studies |
99 | |||
Btk Inhibitors and Resistance Mechanisms - - - - | 11 | Btk Inhibitors and Resistance Mechanisms | |
100 | |||
"Tertiary Lymphoid Structures in Cancer Prognosis" - - - - | 11 | Tertiary Lymphoid Structures in Cancer Prognosis | |
101 | Extrachromosomal DNA in cancer research - - - - | 11 | Extrachromosomal DNA in cancer research |
102 | Smarca2/4 degraders for cancer treatment - - - - | 11 | Smarca2/4 degraders for cancer treatment |
103 | |||
"Epigenetic Regulators and Cancer Treatment" - - - - | 11 | Epigenetic Regulators and Cancer Treatment | |
104 | Bispecific anti-egfr/cmet adc - - - - | 11 | Bispecific anti-egfr/cmet adc |
105 | Transposable elements and cancer - - - - | 10 | Transposable elements and cancer |
106 | |||
"ER Degradation Therapy for Breast Cancer" - - - - | 10 | ER Degradation Therapy for Breast Cancer | |
107 | Macrophage-based therapies in cancer - - - - | 10 | Macrophage-based therapies in cancer |
108 | |||
"Genomic Alterations in NSCLC" - - - - | 10 | Genomic Alterations in NSCLC | |
109 | Bladder Cancer Diagnosis and Monitoring - - - - | 10 | Bladder Cancer Diagnosis and Monitoring |
110 | |||
"Genomic profiling for cancer diagnosis" - - - - | 10 | Genomic profiling for cancer diagnosis | |
111 | TCR Repertoire in Cancer Patients - - - - | 10 | TCR Repertoire in Cancer Patients |
112 | Kras Vaccine Development - - - - | 10 | Kras Vaccine Development |
113 | |||
"G-quadruplex Targeting Compound in Pancreatic Cancer Treatment" - - - - | 9 | G-quadruplex Targeting Compound in Pancreatic Cancer Treatment | |
114 | |||
Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer (MCRC) - - - - | 9 | Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer | |
115 | Liquid biopsy for glioma monitoring - - - - | 9 | Liquid biopsy for glioma monitoring |
116 | |||
Mismatch repair and immune checkpoint inhibitors - - - - | 9 | Mismatch repair and immune checkpoint inhibitors | |
117 | |||
"Immunomodulatory effects of mushroom consumption in prostate cancer." - - - - | 9 | Immunomodulatory effects of mushroom consumption in prostate cancer. | |
118 | Nectin-4 targeted ADCs - - - - | 9 | Nectin-4 targeted ADCs |
119 | Single-cell gene expression technologies - - - - | 9 | Single-cell gene expression technologies |
120 | |||
Head and neck cancer subtyping - - - - | 9 | Head and neck cancer subtyping | |
121 | Cancer Vaccine Development - - - - | 8 | Cancer Vaccine Development |
122 | Proteomic analysis of cancer tissues - - - - | 8 | Proteomic analysis of cancer tissues |
123 | |||
"Lymphoma Prognostics and Treatment Strategies" - - - - | 8 | Lymphoma Prognostics and Treatment Strategies | |
124 | |||
"Chemotherapy Resistance Mechanisms in Colorectal Cancer" - - - - | 8 | Chemotherapy Resistance Mechanisms in Colorectal Cancer | |
125 | Cancer-associated fibroblasts research - - - - | 7 | Cancer-associated fibroblasts research |
126 | |||
Condensate-based drug discovery - - - - | 7 | Condensate-based drug discovery | |
127 | |||
"Metabolism and Cancer Treatment" - - - - | 7 | Metabolism and Cancer Treatment | |
128 | Stat3 degraders for cancer therapy - - - - | 7 | Stat3 degraders for cancer therapy |
129 | Melanoma research and embryonic development - - - - | 7 | Melanoma research and embryonic development |
130 | |||
"Ovarian Cancer Biomarkers" - - - - | 7 | Ovarian Cancer Biomarkers | |
131 | |||
LncRNA and Promoter Regulation in Cancer - - - - | 7 | LncRNA and Promoter Regulation in Cancer | |
132 | Immunotherapy in cancer treatment - - - - | 7 | Immunotherapy in cancer treatment |
133 | |||
"Ferroptosis in Cancer Cells" - - - - | 7 | Ferroptosis in Cancer Cells | |
134 | |||
"Cdk4 Inhibitors and Breast Cancer Resistance" - - - - | 7 | Cdk4 Inhibitors and Breast Cancer Resistance | |
135 | Radiation therapy and DNA damage response inhibitors - - - - | 7 | Radiation therapy and DNA damage response inhibitors |
136 | Liquid biopsy for cancer diagnosis and treatment response. - - - - | 7 | Liquid biopsy for cancer diagnosis and treatment response. |
137 | Brain Metastasis Survival Analysis - - - - | 7 | Brain Metastasis Survival Analysis |
138 | |||
Molecular Biomarkers in Breast Cancer - - - - | 7 | Molecular Biomarkers in Breast Cancer | |
139 | |||
P53 and RPL22 in Cancer - - - - | 7 | P53 and RPL22 in Cancer | |
140 | Colorectal cancer research - - - - | 7 | Colorectal cancer research |
141 | |||
"Tumor Suppression Mechanisms" - - - - | 7 | Tumor Suppression Mechanisms | |
142 | Radiation-induced salivary gland damage and regeneration - - - - | 7 | Radiation-induced salivary gland damage and regeneration |
143 | |||
"Adenosine Signaling and Immunotherapy" - - - - | 7 | Adenosine Signaling and Immunotherapy | |
144 | Sarcopenia and ICI in NSCLC - - - - | 7 | Sarcopenia and ICI in NSCLC |
145 | Ethnic disparities in lymphoma survival - - - - | 7 | Ethnic disparities in lymphoma survival |
146 | Liquid biopsy for lung cancer screening - - - - | 7 | Liquid biopsy for lung cancer screening |
147 | |||
"KDM6A Loss in Urothelial Carcinomas" - - - - | 7 | KDM6A Loss in Urothelial Carcinomas | |
148 | Immuno-oncology screens with CRISPR and RNA-seq - - - - | 6 | Immuno-oncology screens with CRISPR and RNA-seq |
149 | P53 Restoration Therapy - - - - | 6 | P53 Restoration Therapy |
150 | Immunometabolic targeting in cancer immunotherapy - - - - | 6 | Immunometabolic targeting in cancer immunotherapy |
151 | |||
"Breast cancer recurrence and gene regulation" - - - - | 6 | Breast cancer recurrence and gene regulation | |
152 | Head and neck squamous cell carcinoma (HNSCC) research - - - - | 6 | Head and neck squamous cell carcinoma research |
153 | |||
"HCC Immune Cells Study" - - - - | 6 | HCC Immune Cells Study | |
154 | |||
"Pd-L1 IHC Scoring Methods" - - - - | 6 | Pd-L1 IHC Scoring Methods | |
155 | Ovarian Cancer Glycosylation and Metastasis - - - - | 6 | Ovarian Cancer Glycosylation and Metastasis |
156 | |||
"Ubiquitin-Proteasome System in Cancer Treatment" - - - - | 6 | Ubiquitin-Proteasome System in Cancer Treatment | |
157 | |||
Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma - - - - | 6 | Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma | |
158 | Immunotherapy in Non-Small Cell Lung Cancer - - - - | 6 | Immunotherapy in Non-Small Cell Lung Cancer |
159 | Anlotinib + Chemo for Advanced Escc Treatment - - - - | 6 | Anlotinib + Chemo for Advanced Escc Treatment |
160 | |||
"Myc Targeting Technologies" - - - - | 6 | Myc Targeting Technologies | |
161 | Neuroblastoma Epigenetics Study - - - - | 5 | Neuroblastoma Epigenetics Study |
162 | |||
"Metastasis and Genetic Alterations" - - - - | 5 | Metastasis and Genetic Alterations | |
163 | T Cell Exhaustion and Stemness Programs - - - - | 5 | T Cell Exhaustion and Stemness Programs |
164 | |||
Prostate cancer research - - - - | 5 | Prostate cancer research | |
165 | |||
"Lung Cancer Microenvironment Analysis" - - - - | 5 | Lung Cancer Microenvironment Analysis | |
166 | |||
"Pi3k/Akt Inhibitors in Breast Cancer" - - - - | 5 | Pi3k/Akt Inhibitors in Breast Cancer | |
167 | |||
"Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis" - - - - | 5 | Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis | |
168 | Extracellular Vesicle Research in Ovarian Cancer - - - - | 5 | Extracellular Vesicle Research in Ovarian Cancer |
169 | Colorectal Cancer Secondary Malignancies in Young Adults - - - - | 5 | Colorectal Cancer Secondary Malignancies in Young Adults |
170 | Molecular Glues Targeting Cancer-Specific E3 Ligases - - - - | 5 | Molecular Glues Targeting Cancer-Specific E3 Ligases |
171 | Epigenetics and Cancer Research - - - - | 5 | Epigenetics and Cancer Research |
172 | Immunogenic neoantigens and NMD inhibition in cancer immunotherapy - - - - | 5 | Immunogenic neoantigens and NMD inhibition in cancer immunotherapy |
173 | Click Activated Prodrugs Against Cancer Platform - - - - | 5 | Click Activated Prodrugs Against Cancer Platform |
Training hyperparameters
- calculate_probabilities: False
- language: None
- low_memory: False
- min_topic_size: 10
- n_gram_range: (1, 1)
- nr_topics: None
- seed_topic_list: None
- top_n_words: 10
- verbose: True
- zeroshot_min_similarity: 0.7
- zeroshot_topic_list: None
Framework versions
- Numpy: 1.25.2
- HDBSCAN: 0.8.33
- UMAP: 0.5.5
- Pandas: 1.5.3
- Scikit-Learn: 1.2.2
- Sentence-transformers: 2.6.0.dev0
- Transformers: 4.39.0.dev0
- Numba: 0.58.1
- Plotly: 5.15.0
- Python: 3.10.12
- Downloads last month
- 0
This model does not have enough activity to be deployed to Inference API (serverless) yet. Increase its social
visibility and check back later, or deploy to Inference Endpoints (dedicated)
instead.